Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID.
about
Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndromeCharacterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice.Novel MRI tests of orocecal transit time and whole gut transit time: studies in normal subjectsEffect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial.Severity in irritable bowel syndrome: a Rome Foundation Working Team report.A systematic review of measurement properties of the instruments measuring health-related quality of life in patients with irritable bowel syndrome.Commentary on 'Osmotic and stimulant laxatives for the management of childhood constipation'.Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial.Gastrointestinal well-being in subjects reporting mild gastrointestinal discomfort: characteristics and properties of a global assessment measure.
P2860
Q21133920-00D0A4F8-F0AF-4DC5-A3BF-AF8A57E1974DQ30433548-46FA99CE-13B9-44E8-8523-5276E6F2766EQ34853731-EECA78AB-E658-4109-9C0A-9068F409D2F4Q36310200-4FA3150D-E8D4-4954-BB4F-B1A2A4FC51C0Q37900126-D3682D64-07F2-4BE3-8EB4-F6743CF14AEFQ38410293-C9B3849F-48C0-4CBE-A647-B20A6EE56822Q43361635-C9E83A1F-AF66-4FF5-A75D-A8AF3763AB1DQ44404507-B1A1AB22-46FC-4559-83C5-C9277DD2C04BQ48293657-219533D0-730B-43CD-8928-1E8315C3ED46
P2860
Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Rome Foundation Endpoints and ...... izing Clinical Trials in FGID.
@en
Rome Foundation Endpoints and ...... izing Clinical Trials in FGID.
@nl
type
label
Rome Foundation Endpoints and ...... izing Clinical Trials in FGID.
@en
Rome Foundation Endpoints and ...... izing Clinical Trials in FGID.
@nl
prefLabel
Rome Foundation Endpoints and ...... izing Clinical Trials in FGID.
@en
Rome Foundation Endpoints and ...... izing Clinical Trials in FGID.
@nl
P2860
P356
P1476
Rome Foundation Endpoints and ...... izing Clinical Trials in FGID.
@en
P2093
Douglas A Drossman
P2860
P304
P356
10.1038/AJG.2010.49
P407
P577
2010-04-01T00:00:00Z